HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
1 - 21 of 21
Dr. Davidson works to understand the molecular basis of childhood onset neurodegenerative diseases and the development of gene and small molecule therapies for treatment. She also focuses on how noncoding RNAs participate in neural development and neurodegenerative disease processes, and how they can be harnessed for therapies.
Dr. De Leon-Crutchlow’s translational research program focuses on examining the pathophysiology of disorders of insulin regulation, identifying novel therapeutic targets, and developing new therapies for these conditions. The program approach includes patient-oriented research and bench research employing mouse models and primary islet cultures.
Dr. De Raedt researches pediatric high grade glioma development and aims to understand the involvement of crucial pathways. He investigates pathway interaction, and explores ways to develop therapies through analyzing human tumors, performing cellular studies, and developing accurate mouse models. This allows Dr. De Raedt and his team to perform novel pre-clinical studies that can lead to clinical trials.
Dr. Deardorff’s work integrates patient information with genomics and cell biology to diagnosis and understand rare genetic disease. His research focuses on disorders caused by dysregulation of chromatin or altered translational regulation, specifically, Cornelia de Lange, Coffin-Siris, Skraban-Deardorff and KBG syndromes.
Dr. DeMauro has special expertise in rigorous assessment of early childhood outcomes of high-risk neonates. Her research focuses on improving outcomes of children with bronchopulmonary dysplasia and school-age assessment of functional outcomes in preterm-born children.
Dr. Diskin's research is focused on translational genomics in childhood cancers. Her laboratory seeks to identify the genetic basis of childhood cancers by combining quantitative computational methods with rigorous "wet-lab" experimental approaches. In parallel, she has developed, and is applying, a proteogenomic approach to identify novel immunotherapeutic targets for high-risk and relapsed pediatric malignancies.
Dr. Dlugos is the director of the Section of Clinical Neurophysiology at Children’s Hospital of Philadelphia. He studies epilepsy genetics, pharmacogenetics, and epilepsy surgery. He is also a core faculty member of the ENGIN Frontier Program.
Dr. Douglas has extensive laboratory experience investigating the cellular immunology of HIV/AIDS, primary immune deficiency diseases, and cellular immunopathologies. In addition, he has had significant involvement in studies related to immunological interactions.
Dr. Doupnik’s research investigates how to ensure that children can access effective mental health services. She uses methods from diverse fields, including epidemiology, comparative effectiveness, and health policy research. Currently, she is focused on suicide prevention and integration of mental health services into children’s hospitals.
The research interests of Dr. Downes focus on antimicrobial clinical pharmacology and pharmacoepidemiology in children with a goal to identify novel approaches to optimize efficacy, minimize toxicity, and limit antimicrobial resistance from antibiotics.
Dr. Dowshen focuses on improving the health outcomes for adolescent and young adults (AYA) living with or at high risk for contracting HIV/AIDS and improving access and quality of care for gender expansive and transgender children and adolescents. She is particularly interested in developing and testing digital health interventions to reach, engage, and retain AYA in care.